Home
About Us
Group Introduction
Founder Introduction
Global Cooperation
Nanolattix Biotechnology
Company Profile
Development History
Research Layout
Nanolattix Health
Extraction Platform
Cosmetics
Machine
Food Brand
Disinfection
Oem/Odm
News
Company News
Industry News
Contact Us
简体中文
English
Release time:
2025-01-10
Nanolattix Submits Dual IND Applications for Cancer Drug T320 in China and the U.S
Tag:
Previous Page
2024.11
2024.5
Next Page
Previous Page:
Next page:
recommend News
Nanolattix Chairperson Dr. Zhican Qu Attends BIO 2025, Showcasing China's Biopharma Innovation
2025-07-09
Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug
Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies
Dr. Qu Zhican Takes Stage at 2025 China Pharmaceutical Innovation Summit and Delivers Keynote Speeches on RDC and ADC
2025-12-01
Nanolattix Attends 10th Guangzhou (Greater Bay Area) Biopharma Innovation Summit, Shares Advancements in ADC and RDC Therapeutics
2025-11-11
Share
